Stratum Market Research
Contact

Healthcare & Life SciencesEuropean UnionUpdated 4 Nov 2026

Antimalarial drugs Market 2026: trade data and key figures

The EU imported €15.5 million of antimalarial drugs and related goods (CN 30046000) from outside the EU in 2025. That was 97% less than in 2020. Canada was the largest outside supplier.

Choose an editionGet a free sample
Region
European Union
Evidence
18 sourced figures from 7 sources
Last checked
4 Nov 2026
Extra-EU imports of CN 30046000, EUR million20202025

15.5EUR million

EU imports from outside the EU, 2025

-97% change

Extra-EU imports of CN 30046000 were down 97% in 2025 compared with 2020 (€568.8 million), calculated from Eurostat values.

18.5EUR million

EU exports of CN 30046000 to countries outside the EU were worth €18.5 million in 2025.

106.1EUR million

Trade between EU member states in CN 30046000 (intra-EU arrivals) came to €106.1 million in 2025.

OverviewDataBuyers and suppliersWhat is insideFAQ

What this market covers

Medicines used to treat and prevent malaria infection. Main buyers are public health programs, aid agencies and hospitals in endemic regions.

Typical segments

  • Artemisinin combination therapy
  • Chloroquine and related drugs
  • Preventive tablets for travellers
  • Severe malaria injectables
ChartExtra-EU imports of CN 30046000, EUR million
Extra-EU imports of CN 30046000, EUR million01503004506002020: 569 EUR million56920202021: 1.6 EUR million20212022: 2.6 EUR million20222023: 2.8 EUR million20232024: 4 EUR million20242025: 15.5 EUR million15.52025

Source: Eurostat

Why this market is moving now

  • Extra-EU import value moved -97% from 2020 to 2025, a direct read on EU demand for sourced supply.
  • Supply is concentrated: one country provided a large share of extra-EU imports in 2025.
  • US employment in the core industry shifted +8% since 2020.
  • Clinical research is active, with studies recruiting now.

Key figures

Each figure names the source it came from. Open the source list below to read the quoted line.

FigureValueYearSource
The EU imported €15.5 million of products under CN code 30046000 (Medicaments containing any of the following antimalarial active principles: artemisinin) from outside the EU in 2025.15.5 EUR million2025Eurostat
Extra-EU imports of CN 30046000 were down 97% in 2025 compared with 2020 (€568.8 million), calculated from Eurostat values.-97 % change2025Eurostat
EU exports of CN 30046000 to countries outside the EU were worth €18.5 million in 2025.18.5 EUR million2025Eurostat
Trade between EU member states in CN 30046000 (intra-EU arrivals) came to €106.1 million in 2025.106.1 EUR million2025Eurostat
Canada was the largest non-EU supplier of CN 30046000 to the EU in 2025, with €11.1 million, or 72% of extra-EU imports.11.1 EUR million2025Eurostat
EU exports of CN 30046000 to the United States were €116 thousand in 2025.116 EUR thousand2025Eurostat
The average value of extra-EU imports of CN 30046000 was €577.56 per kilogram in 2025, calculated from Eurostat value and weight.577.56 EUR per kg2025Eurostat
Germany was the largest EU exporter of CN 30046000 to non-EU countries in 2025, at €7.0 million.7.0 EUR million2025Eurostat
The EU had 3,116 enterprises in NACE class C2120 (Manufacture of pharmaceutical preparations) in 2023.3,116 enterprises2023Eurostat
EU enterprises in NACE class C2120 had net turnover of €428.65 billion in 2023.428.65 EUR billion2023Eurostat
NACE class C2120 employed 600,730 people across the EU in 2023.600,730 persons employed2023Eurostat
The US had 5,013 private establishments in NAICS 325412 (Pharmaceutical preparation manufacturing) in 2025.5,013 establishments2025U.S. Bureau of Labor Statistics
NAICS 325412 employed an average of 229,922 people in US private industry in 2025.229,922 jobs2025U.S. Bureau of Labor Statistics
US employment in NAICS 325412 changed by +8% between 2020 (212,670 jobs) and 2025, calculated from BLS figures.+8 % change2025U.S. Bureau of Labor Statistics
Average annual pay in US NAICS 325412 was $158,377 in 2025.158,377 USD per year2025U.S. Bureau of Labor Statistics
ClinicalTrials.gov lists 1,490 registered studies for the condition "malaria".1,490 registered studies2026U.S. National Library of Medicine
54 of those studies were recruiting participants when checked in November 2026.54 recruiting studies2026U.S. National Library of Medicine
PubMed indexed 227 papers mentioning "antimalarials" in the title or abstract in 2025.227 papers2025U.S. National Library of Medicine

Sources and method

The figures on this page come from the public sources listed below. Read how we work.

  1. Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
    Quoted lines
    • Figure 1DS-045409, reporter EU27_2020, product 30046000, partner EXT_EU27_2020, flow import, 2025, VALUE_IN_EUROS 15498285
    • Figure 2DS-045409, reporter EU27_2020, product 30046000, flow import, 2020 VALUE_IN_EUROS 568760920; 2025 VALUE_IN_EUROS 15498285
    • Figure 3DS-045409, reporter EU27_2020, product 30046000, partner EXT_EU27_2020, flow export, 2025, VALUE_IN_EUROS 18502792
    • Figure 4DS-045409, reporter EU27_2020, product 30046000, partner INT_EU27_2020, flow import, 2025, VALUE_IN_EUROS 106104409
    • Figure 5DS-045409, reporter EU27_2020, product 30046000, partner CA, flow import, 2025, VALUE_IN_EUROS 11095163
    • Figure 6DS-045409, reporter EU27_2020, product 30046000, partner US, flow export, 2025, VALUE_IN_EUROS 116294
    • Figure 7DS-045409, reporter EU27_2020, product 30046000, flow import, 2025, VALUE_IN_EUROS 15498285, QUANTITY_IN_100KG 268
  2. Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
    Quoted lines
    • Figure 8DS-045409, reporter DE, product 30046000, partner EXT_EU27_2020, flow export, 2025, VALUE_IN_EUROS 6998514
  3. Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
    Quoted lines
    • Figure 9sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs ENT_NR, 2023, 3116
    • Figure 10sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs NETTUR_MEUR, 2023, 428651
    • Figure 11sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs EMP_NR, 2023, 600730
  4. U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325412, 2025 (2026-11-04)
    Quoted lines
    • Figure 12QCEW 2025 annual, US000, private, NAICS 325412, annual_avg_estabs 5013
    • Figure 13QCEW 2025 annual, US000, private, NAICS 325412, annual_avg_emplvl 229922
    • Figure 14QCEW 2020 annual_avg_emplvl 212670; 2025 annual_avg_emplvl 229922
    • Figure 15QCEW 2025 annual, US000, private, NAICS 325412, avg_annual_pay 158377
  5. U.S. National Library of Medicine: ClinicalTrials.gov API v2, condition "malaria" (2026-11-04)
    Quoted lines
    • Figure 16query.cond=malaria totalCount 1490
  6. U.S. National Library of Medicine: ClinicalTrials.gov API v2, condition "malaria", status recruiting (2026-11-04)
    Quoted lines
    • Figure 17filter.overallStatus=RECRUITING totalCount 54
  7. U.S. National Library of Medicine: PubMed search "antimalarials"[tiab] AND 2025[dp] (2026-11-04)
    Quoted lines
    • Figure 18esearch count 227

Buyers and suppliers

Who buys

  • Public health programs
  • Aid agencies
  • Hospitals

Large non-EU suppliers to the EU

  1. Canada11.1 EUR million
  2. United States2.6 EUR million
  3. United Kingdom0.6 EUR million
  4. Türkiye0.2 EUR million
  5. Australia0.0 EUR million
  6. Senegal0.0 EUR million

What the full report covers

  1. 01Executive summary
    The answer in one page: size, direction and what moves it
  2. 02Market definition and scope
    What is in and out of the European Union market
  3. 03Market size, 2021 to 2025
    Historical series and growth rates
  4. 04Outlook to 2031
    Base, low and high scenarios with stated assumptions
  5. 05Rules, policy and deadlines
    Regulation and programmes that change demand
  6. 06Drivers and barriers
    What accelerates or slows adoption, by customer segment
  7. 07Prices, costs and margins
    Unit economics where public data allows
  8. 08Competitive landscape
    8 to 12 company profiles with recent moves
  9. 09Opportunities and risks
    For new entrants, suppliers and investors
  10. 10Method and sources
    Every assumption and source, listed

Included with the full report

  • PDF report, 40 to 60 pages
  • Excel data pack
  • Ready-to-use charts
  • Method note and assumptions
  • Written to order in 5 working days
Compare the editions

Frequently asked questions

How big is the EU antimalarial drugs market?

There is no single official market total. Eurostat trade data shows the EU imported €15.5 million of goods under CN 30046000 from outside the EU in 2025 and exported €18.5 million.

Where does the EU import antimalarial drugs from?

Canada was the largest non-EU supplier in 2025. Other large suppliers included United States, United Kingdom, Türkiye.

What is the average import price of antimalarial drugs in the EU?

Dividing Eurostat import value by weight gives about €577.56 per kilogram for CN 30046000 in 2025.

Which EU countries export the most antimalarial drugs?

Germany led EU exports to non-EU countries in 2025, followed by France, Ireland.

How many clinical trials study malaria?

ClinicalTrials.gov lists 1,490 registered studies.

How many US companies are in the antimalarial drugs industry?

BLS counts 5,013 private establishments in NAICS 325412 (Pharmaceutical preparation manufacturing), the closest official industry.

Free sample

Get a free sample of this report

We send the table of contents, two sample chapters and the method note, usually within one working day. You owe us nothing for asking.

  • Full table of contents
  • Two sample chapters
  • Method note and data outline
A market, a region or the decision you are making helps us pick the right chapters.

We use your details only to reply. See our privacy policy.

Full report $3,450Choose an edition

Related markets

More in Healthcare & Life Sciences

Buyers also read

Explore byAll Healthcare & Life Sciences marketsMarkets starting with AReport library